The trefoil factor 1 (TFF1) protein involved in doxorubicin-induced apoptosis resistance is upregulated by estrogen in breast cancer cells

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1518-1526

  Pelden, Sonam ^a   Insawang, Tonkla ^a   Thuwajit, Chanitra ^a   Thuwajit, Peti ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Apoptosis; Breast cancer; Doxorubicin; Estrogen; Trefoil factor 1 protein

Indexed keywords

CATALASE; DOXORUBICIN; ESTRADIOL; ESTROGEN; FULVESTRANT; SECRETORY PROTEIN; TREFOIL FACTOR 1 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE; GENE SILENCING; GENE TARGETING; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TFF1 GENE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, NEUTRALIZING; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CATALASE; CELL PROLIFERATION; DOXORUBICIN; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; PROTEIN ARRAY ANALYSIS; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84880644758     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2593     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Porter P: Westernizing' women's risks? Breast cancer in lower-income countries. N Engl J Med 358: 213-216, 2008.
3. Tuttle TM, Rueth NM, Abbott A and Virnig BA: United States trends in the surgical treatment of primary breast cancer. World J Surg 36: 1475-1479, 2012.
4. Arslan C, Altundag K and Dizdar O: Emerging drugs in metastatic breast cancer: an update. Expert Opin Emerg Drugs 16: 647-667, 2011.
5. Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA and Rugo HS: The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis 29: 807-819, 2012.
6. Jordan VC and O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25: 5815-5824, 2007.
7. Allegra JC, Lippman ME, Thompson EB and Simon R: An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer. Cancer Res 38: 4299-4304, 1978.
8. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
9. Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S and Andre F: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 18: 1477-1483, 2007.
10. Pritchard JE, Dillon PM, Conaway MR, Silva CM and Parsons SJ: A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model. Oncology 83: 305-320, 2012.
11. Dickson RB and Stancel GM: Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 2000: 135-145, 2000.
12. Lewis-Wambi JS and Jordan VC: Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11: 206, 2009
13. Haddow A, Watkinson JM, Paterson E and Koller PC: Influence of synthetic oestrogens on advanced malignant disease. Br Med J 2: 393-398, 1944.
14. Ward HW: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13-14, 1973.
15. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS and Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759, 2005.
16. Gompel A, Somaï S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M and Rostène W: Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65: 593-598, 2000.
17. Teixeira C, Reed JC and Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
18. Perillo B, Sasso A, Abbondanza C and Palumbo G: 17β-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901, 2000.
19. Rio MC and Chambon P: The pS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells 2: 269-274, 1990.
20. Bossenmeyer-Pourié C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C and Rio MC: The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 157: 761-770, 2002.
21. Buron N, Guery L, Creuzot-Garcher C, Lafontaine PO, Bron A, Rio MC and Solary E: Trefoil factor TFF1-induced protection of conjunctival cells from apoptosis at premitochondrial and postmitochondrial levels. Invest Ophthalmol Vis Sci 49: 3790-3798, 2008.
22. Nunez AM, Jakowlev S, Briand JP, Gaire M, Krust A, Rio MC and Chambon P: Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 121: 1759-1765, 1987.
23. Tomasetto C and Rio MC: Pleiotropic effects of Trefoil Factor 1 deficiency. Cell Mol Life Sci 62: 2916-2920, 2005.
24. Ruchaud-Sparagano MH, Westley BR and May FE: The trefoil protein TFF1 is bound to MUC5AC in human gastric mucosa. Cell Mol Life Sci 61: 1946-1954, 2004.
25. Madsen J, Nielsen O, Tornøe I, Thim L and Holmskov U: Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem 55: 505-513, 2007.
26. Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, May FE, Westley BR, Tepsiri NN, Paupairoj A and Chau-In S: Increased TFF1 trefoil protein expression in Opisthorchis viverrini-associated cholangiocarcinoma is important for invasive promotion. Hepatol Res 37: 295-304, 2007.
27. Prest SJ, May FE and Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 16: 592-594, 2002.
28. Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A, Correa P, Peek RM Jr and El-Rifai W: Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest 121: 1753-1767, 2011.
29. Gillesby BE and Zacharewski TR: pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res Treat 56: 253-265, 1999.
30. Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W and Stamp GW: Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 183: 30-38, 1997.
31. Reshkin SJ, Tedone T, Correale M, Mangia A, Casavola V and Paradiso A: Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies. Cell Prolif 32: 107-118, 1999.
32. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK, Mertani HC, Zhu T, Liu D and Lobie PE: Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 150: 4473-4483, 2009.
33. Buache E, Etique N, Alpy F, Stoll I, Muckensturm M, Reina-San-Martin B, Chenard MP, Tomasetto C and Rio MC: Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene 30: 3261-3273, 2011.
34. Miller WR: Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 118: 273-276, 2010.
35. Zhou L, Yan T, Jiang Y, Di G, Shen Z, Shao Z and Lu J: Prognostic and predictive value of TFF1 for adjuvant endocrine therapy in Chinese women with early ER positive breast cancer: comparing aromatase inhibitors with tamoxifen. Breast 20: 15-20, 2011.
36. Sinha AK: Colorimetric assay of catalase. Anal Biochem 47: 389-394, 1972.
37. Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JM, Dalton WS and Chin KV: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 60: 4161-4166, 2000.
38. Troester MA, Hoadley KA, Sorlie T, Herbert BS, Borresen-Dale AL, Lonning PE, Shay JW, Kaufmann WK and Perou CM: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64: 4218-4226, 2004.
39. Elmore LW, Di X, Dumur C, Holt SE and Gewirtz DA: Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 11: 2637-2643, 2005.
40. Mobley JA and Brueggemeier RW: Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 25: 3-9, 2004.
41. Sastre-Serra J, Valle A, Company MM, Garau I, Oliver J and Roca P: Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med 48: 506-512, 2010.
42. O'Sullivan J, Whyte L, Drake J and Tenniswood M: Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ 10: 914-927, 2003.
43. Won YS, Lee SJ, Yeo SG and Park DC: Effects of female sex hormones on clusterin expression and paclitaxel resistance in endometrial cancer cell lines. Int J Med Sci 9: 86-92, 2012.
44. Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H and Miyoshi S: Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci 102: 2038-2042, 2011.
45. de Vincenzo R, Scambia G, Benedetti Panici P, Bonanno G, Ercoli A, Fattorossi A, Pernisco S, Isola G and Mancuso S: Chemosensitizing effect of tamoxifen and ICI 182,780 on parental and adriamycin-resistant MCF-7 human breast cancer cells. Ann NY Acad Sci 784: 517-520, 1996.